The MS Wire - A Column by Ed Tobias

Florida, MS biomarker, Lemtrada, nasal spray Diagnosed with MS at age 32 in 1980, Ed has written the "MS Wire" column for Multiple Sclerosis News Today since August 2016. He presents timely information on MS, blended with personal experiences. Before retiring from full-time work in 2012, Tobias spent more than four decades in broadcast and on-line newsrooms as a manager, reporter, and radio news anchor. He’s won several national broadcast awards. As an MS patient communicator, Ed consults with healthcare and social media companies. He’s the author of “We’re Not Drunk, We Have MS: A tool kit for people living with multiple sclerosis.” Ed and his wife split time between the Washington, D.C. suburbs and Florida’s Gulf Coast.

My Lemtrada Journey: Round 2, Plus 7 Months

I’m coming up on the second anniversary of my Lemtrada (alemtuzumab) treatment. My first infusion round was the first week of December 2016. Round 2, delayed by four months, was done last April. So, it’s time to update my Lemtrada journey for you. Lemtrada, in case you’re not…

FDA Warns of Possible Dangers of Stopping Gilenya

If you are being treated with Gilenya, take note. The U.S. Food and Drug Administration is warning that if you stop using Gilenya (fingolimod), there’s a chance your MS could become worse. The FDA issued a safety alert saying that this only happens rarely, but when it does, the…

When You’ve Gotta Go, but There’s No Place to Do It

We’ve all been there. That “uh-oh” feeling hits and you know you’ll be in trouble if you can’t find a restroom, fast. You hope the clerk in the store with the “Restrooms for Customers Only” sign will make an exception if you tell her it’s about to run down…

MS, a Foot Brace, and a Car Crash

A tragic car crash involving a man with MS is a reminder that we all should be just a little bit more careful than the average driver when we get behind the wheel. The accident happened in early October on a street in Eugene, Oregon. As reported by…

MS and the Flu Shot: What If You Don’t Want One?

I’ve written several times about MS and the flu. I’ve always encouraged people to get an annual flu shot, but I know some people, for whatever reasons, don’t get one. I know I’ll never convince some of you of the benefits of this shot, no matter how much…

Thinking About Selma Blair and Her MS

By now you may have heard that actress Selma Blair has revealed that she has multiple sclerosis (MS). That took a lot of guts. Those of us who share her diagnosis might learn a few things from what she’s shared and how she’s shared it. Blair may be…

FTC Challenges Amniotic Stem Cell Treatment Clinics’ Claims

“Deceptive” and “false” are two words used by the U.S. Federal Trade Commission (FTC) to describe marketing claims by two stem cell treatment clinics in California. According to an FTC complaint, the clinics had been advertising that they were using amniotic stem cell therapy to successfully treat serious diseases, including…

New Rules May Bring Updated Rights to Flyers with Disabilities

Flying isn’t what it used to be, as everyone who’s taken a flight in the past 15 years or so knows. Flyers with disabilities can have a particularly challenging time dealing with airports, airlines, and aircraft. Airports are crowded and stretch forever. Airplanes are crowded, their seats are small,…

I’m Too Tired to Write Tonight

Please forgive me, but I’m too tired to write tonight. My wife had surgery last week, so I’ve been doing a couple of things that I haven’t done much in the 42 years since our wedding: shopping and cooking. (Well, making Harris Teeter ready-to-heat meals, that is. For…

MS Patients Capture the Ear of a Pharma Company

People with multiple sclerosis (MS) rarely get the opportunity to talk to the people who design their medications. But a new collaboration is providing that opportunity to a few of us. The Accelerated Cure Project for Multiple Sclerosis (ACP) and pharmaceutical manufacturer EMD Serono have begun working together…

Buddy, Can You Give Me a Lift to the Doctor?

Is getting from home to a healthcare appointment a pain in the butt for you? Do you have to search for someone to take you? Do you haul yourself into your car and hope that you can find a nearby parking spot? Is public transportation impossible to find where…

Serious DMTs Need Serious Care Coordination

Ocrevus (ocrelizumab) is a serious disease-modifying therapy. It has the potential to deliver a major blow to a patient’s MS, but it also carries the possibility of severe side effects. The protocol for Ocrevus requires different doses on different infusion dates, following a specific treatment schedule. It’s also…

Wearables Focus on Tracking Your Health

I never thought I’d want a wearable internet device until I got an Apple Watch for my birthday. One of its neat apps tracks the laps that I swim, the steps that I (try to) take, and my pulse rate. The watch can even link up with some high-tech…

Pharma Exec Calls a 400 Percent Price Hike ‘Moral.’ Is it?

Is quadrupling the price of a medication “moral”? One pharmaceutical CEO not only thinks so, but he also says it’s a “moral requirement.” The medication is liquid nitrofurantoin, an antibiotic mixture that’s primarily used to treat bladder and urinary tract infections. Since UTIs can be a problem for people…

A Generic for Ampyra Could Be Released Soon

Editor’s note: Shortly after this column was published, Mylan pharmaceuticals announced it will begin distributing Dalfampridine Extended-Release Tablets, 10 mg, the authorized generic version of Acorda’s Ampyra. There’s been no word, yet, on what it will cost or how soon the generic will become available in pharmacies. A few…

Things to Know About Flu Shots if You Have MS

The start of flu season here in the United States is just a few weeks away. It’s time for my wife and me to get our flu shots, just as we have for as long as I can remember. My neurologist and our primary care physician both recommend the…

Ocrevus Predicted to Be a Billion-dollar Blockbuster

Ocrevus, a disease-modifying MS treatment that’s only been on the market a little less than 18 months, appears poised to be a cash cow for its maker, Genentech. The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical industry, predicts that Ocrevus is “poised to…